These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

949 related items for PubMed ID: 17304143

  • 1. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine.
    Dilger K, Schaeffeler E, Lukas M, Strauch U, Herfarth H, Müller R, Schwab M.
    Ther Drug Monit; 2007 Feb; 29(1):1-5. PubMed ID: 17304143
    [Abstract] [Full Text] [Related]

  • 2. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
    Wong DR, Pierik M, Seinen ML, van Bodegraven AA, Gilissen LP, Bus P, Bakker JA, Masclee AA, Neef C, Engels LG, Hooymans PM.
    J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
    [Abstract] [Full Text] [Related]

  • 3. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.
    Roblin X, Peyrin-Biroulet L, Phelip JM, Nancey S, Flourie B.
    Am J Gastroenterol; 2008 Dec; 103(12):3115-22. PubMed ID: 19086961
    [Abstract] [Full Text] [Related]

  • 4. Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study.
    Gisbert JP, Luna M, Maté J, González-Guijarro L, Cara C, Pajares JM.
    Hepatogastroenterology; 2006 Dec; 53(69):399-404. PubMed ID: 16795981
    [Abstract] [Full Text] [Related]

  • 5. Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease.
    Hindorf U, Lyrenäs E, Nilsson A, Schmiegelow K.
    Scand J Gastroenterol; 2004 Nov; 39(11):1105-12. PubMed ID: 15545169
    [Abstract] [Full Text] [Related]

  • 6. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
    Gearry RB, Barclay ML.
    J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
    [Abstract] [Full Text] [Related]

  • 7. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
    Kwan LY, Devlin SM, Mirocha JM, Papadakis KA.
    Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898
    [Abstract] [Full Text] [Related]

  • 8. Impact of thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations in patients with chronic inflammatory diseases.
    Schedel J, Gödde A, Schütz E, Bongartz TA, Lang B, Schölmerich J, Müller-Ladner U.
    Ann N Y Acad Sci; 2006 Jun; 1069():477-91. PubMed ID: 16855176
    [Abstract] [Full Text] [Related]

  • 9. Monitoring 6-thioguanine nucleotide concentrations in Japanese patients with inflammatory bowel disease.
    Andoh A, Tsujikawa T, Ban H, Hashimoto T, Bamba S, Ogawa A, Sasaki M, Saito Y, Fujiyama Y.
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1373-7. PubMed ID: 18662197
    [Abstract] [Full Text] [Related]

  • 10. Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels.
    Angelberger S, Schaeffeler E, Teml A, Petritsch W, Shonova O, Lukas M, Bar-Meir S, Dilger K, Greinwald R, Mueller R, Stange EF, Herrlinger KR, Schwab M, Reinisch W.
    Inflamm Bowel Dis; 2013 Mar; 19(3):590-8. PubMed ID: 23388543
    [Abstract] [Full Text] [Related]

  • 11. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold.
    Gardiner SJ, Gearry RB, Begg EJ, Zhang M, Barclay ML.
    Clin Gastroenterol Hepatol; 2008 Jun; 6(6):654-60; quiz 604. PubMed ID: 18467186
    [Abstract] [Full Text] [Related]

  • 12. The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients.
    Gilissen LP, Bierau J, Derijks LJ, Bos LP, Hooymans PM, van Gennip A, Stockbrügger RW, Engels LG.
    Aliment Pharmacol Ther; 2005 Oct 01; 22(7):605-11. PubMed ID: 16181300
    [Abstract] [Full Text] [Related]

  • 13. 6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine.
    Roblin X, Serre-Debeauvais F, Phelip JM, Faucheron JL, Hardy G, Chartier A, Helluwaert F, Bessard G, Bonaz B.
    Aliment Pharmacol Ther; 2005 Apr 01; 21(7):829-39. PubMed ID: 15801918
    [Abstract] [Full Text] [Related]

  • 14. Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease?
    Fangbin Z, Xiang G, Minhu C, Liang D, Feng X, Min H, Pinjin H.
    Ther Drug Monit; 2012 Dec 01; 34(6):695-701. PubMed ID: 23149442
    [Abstract] [Full Text] [Related]

  • 15. Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice.
    Gearry RB, Barclay ML, Roberts RL, Harraway J, Zhang M, Pike LS, George PM, Florkowski CM.
    Intern Med J; 2005 Oct 01; 35(10):580-5. PubMed ID: 16207256
    [Abstract] [Full Text] [Related]

  • 16. Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis.
    Heneghan MA, Allan ML, Bornstein JD, Muir AJ, Tendler DA.
    J Hepatol; 2006 Oct 01; 45(4):584-91. PubMed ID: 16876902
    [Abstract] [Full Text] [Related]

  • 17. Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients.
    González-Lama Y, Bermejo F, López-Sanromán A, García-Sánchez V, Esteve M, Cabriada JL, McNicholl AG, Pajares R, Casellas F, Merino O, Carpio D, Vera MI, Muñoz C, Calvo M, Benito LM, Bujanda L, García-Fernández FJ, Ricart E, Ginard D, Velasco M, Carneros JA, Manceñido N, Calvo M, Algaba A, Froilan C, Cara C, Maté J, Abreu L, Gisbert JP, "Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU)".
    Aliment Pharmacol Ther; 2011 Sep 01; 34(5):544-54. PubMed ID: 21722149
    [Abstract] [Full Text] [Related]

  • 18. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial.
    Reinisch W, Angelberger S, Petritsch W, Shonova O, Lukas M, Bar-Meir S, Teml A, Schaeffeler E, Schwab M, Dilger K, Greinwald R, Mueller R, Stange EF, Herrlinger KR, International AZT-2 Study Group.
    Gut; 2010 Jun 01; 59(6):752-9. PubMed ID: 20551460
    [Abstract] [Full Text] [Related]

  • 19. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients.
    Gisbert JP, Niño P, Rodrigo L, Cara C, Guijarro LG.
    Am J Gastroenterol; 2006 Dec 01; 101(12):2769-76. PubMed ID: 17026564
    [Abstract] [Full Text] [Related]

  • 20. Thiopurine methyltransferase gene polymorphisms in Chinese patients with inflammatory bowel disease.
    Cao Q, Zhu Q, Shang Y, Gao M, Si J.
    Digestion; 2009 Dec 01; 79(1):58-63. PubMed ID: 19252404
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.